Cite
HARVARD Citation
Folegatti, P. et al. (2020). Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet infectious diseases. 20 (7), pp. 816-826. [Online].